Jeonbuk National University Hospital | Clinical Pharmacology Center
Status and phase
Conditions
Treatments
Study type
Funder types
Identifiers
About
This is a phase 3 study to evaluate zimberelimab (AB122) combined with domvanalimab (AB154) compared to pembrolizumab in front-line, PD-L1-high, locally advanced or metastatic NSCLC.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Histologically confirmed, treatment naïve, locally advanced or metastatic (stage IIIB IV per AJCC version 8), squamous or non-squamous NSCLC with documented high PD L1 expression (TC ≥ 50%) as determined by the VENTANA SP263 IHC assay, as assessed by central laboratories).
Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1
Must have at least 1 measurable lesion per RECIST v1.1
Adequate organ and marrow function
If a participant has brain or meningeal metastases, the participant must meet the following criteria:
Exclusion criteria
Other protocol defined Inclusion/Exclusion criteria may apply.
Primary purpose
Allocation
Interventional model
Masking
169 participants in 5 patient groups
Loading...
Central trial contact
Medical Director
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal